04:37 PM EDT, 08/06/2024 (MT Newswires) -- Halozyme Therapeutics ( HALO ) reported Q2 non-GAAP EPS late Tuesday of $0.91, up from $0.74 a year earlier.

Analysts surveyed by Capital IQ expected $0.76.

Revenue for the quarter ended June 30 was $231.4 million, up from $221 million a year earlier.

Analysts surveyed by Capital IQ expected $204.9 million.

In 2024, the company expects non-GAAP diluted EPS of $3.65 to $4.05 on revenue of $935 million to $1.02 billion. Analysts expect EPS of $3.94 on revenue of $983.7 million.

Halozyme said it completed a $250 million accelerated share repurchase launched in November 2023, buying 6.5 million shares at $38.35 each, ending a three-year program that repurchased 19.1 million shares at an average price of $39.31.

Price: 54.00, Change: +2.06, Percent Change: +3.97